Abstract 1324: Evaluation of KIF14 in a chemotherapeutic resistant breast cancer cell line

Abstract The purpose of this study is to elucidate the mechanisms of KIF14 in acquired paclitaxel chemoresistance in a breast cancer cell line by evaluating its expression, activity, and regulatory network. Chemoresistance remains the single greatest cause of therapeutic failure in cancer therapeutics. Development of chemoresistance for compounds that often only suppress growth and do not eliminate tumors has been shown to correlate with more severe clinical phenotypes. Paclitaxel, the microtubule stabilizing compound, has been shown to be of particular importance in the study of chemoresistance as its therapeutic efficacy has been directly shown to be tempered by resistance. Whole transcriptome analysis of long-term chemoresistant breast cancer cells generated at Indiana State University identified a gene not previously reported to play a role in the acquired chemoresistance of breast cancer, kinesin family member 14, KIF14 (Table 1). A knockdown of KIF14 in a chemoresistant breast cancer cell line was performed using Lipofectamine™ 3000 Transfection Reagent. Western Analysis and RT- PCR was performed to confirm the expression of the gene both before and after knockdown was performed. Once expression alterations were confirmed, a proliferation assay, population doubling assay, and a colony formation assay were performed to explore the effects of the gene knockdown in response to paclitaxel treatment. Findings from these studies identify a potential role for KIF14 and microtubule dynamics in acquired chemoresistance against paclitaxel. KIF14 sequencing analysis performed using Illumina HiSeq4000 technology in chemoresistant cellsGeneLog2 Fold Change in Resistant CellsP-valueFDRKIF141.592.83x10-154.18x10-14 Citation Format: Keeley Cleghorn, Catherine E. Steding. Evaluation of KIF14 in a chemotherapeutic resistant breast cancer cell line [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1324.